Daljit Singh Aurora Sells $270K of Neumora Therapeutics Inc (NMRA) — SEC Form 4, Aug 21, 2026
Open-Market Net Sale · SEC Form 4
−$269,967
Equity Position
183K sh
183,202 → 183,202
Filing Lag
0 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Daljit Singh Aurora CIK 0001793971 |
Officer
|
Daljit Singh Aurora at Neumora Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$1,030,583
More from this insider at Neumora Therapeutics Inc
| 2026-08-19 | Sell | -$431,674 | View |
| 2026-02-19 | Sell | -$21,917 | View |
| 2026-01-09 | Award | — | View |
| 2025-11-13 | Sell | -$307,025 | View |
| 2025-05-30 | Award | — | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-20 | M - Exercise | 67,741 A | $0.72 | +$48,774 | 116,491 | Direct |
| Common StockF1 | 2026-08-20 | S - Sale | 67,741 D | $1.51 | -$102,587 | 48,750 | Direct |
| Common StockF3 | 2026-08-20 | M - Exercise | 21,685 A | $0.72 | +$15,613 | 21,685 | Indirect See footnote |
| Common StockF3 | 2026-08-20 | M - Exercise | 45,026 A | $0.72 | +$32,419 | 66,711 | Indirect See footnote |
| Common StockF2F3 | 2026-08-20 | S - Sale | 66,711 D | $1.51 | -$101,000 | 0 | Indirect See footnote |
| Common Stock | 2026-08-21 | M - Exercise | 20,553 A | $0.72 | +$14,798 | 69,303 | Direct |
| Common StockF3 | 2026-08-21 | M - Exercise | 21,055 A | $0.72 | +$15,160 | 21,055 | Indirect See footnote |
| Common StockF7 | 2026-08-21 | S - Sale | 20,553 D | $1.59 | -$32,780 | 48,750 | Direct |
| Common StockF8F3 | 2026-08-21 | S - Sale | 21,055 D | $1.60 | -$33,600 | 0 | Indirect See footnote |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $0.72 | 2026-08-20 | M - Exercise | 67,741 D | $0.00 | 2034-02-14 | 67,741 Common Stock | Direct |
| Stock Option (Right to Buy)F5F3 | $0.72 | 2026-08-20 | M - Exercise | 45,026 D | $0.00 | 2033-01-19 | 45,026 Common Stock | Indirect See footnote |
| Stock Option (Right to Buy)F5F3 | $0.72 | 2026-08-20 | M - Exercise | 21,685 D | $0.00 | 2031-09-20 | 21,685 Common Stock | Indirect See footnote |
| Stock Option (Right to Buy)F6 | $1.52 | 2026-08-20 | A - Award/Grant | 200,000 A | $0.00 | 2036-08-20 | 200,000 Common Stock | Direct |
| Stock Option (Right to Buy)F4 | $0.72 | 2026-08-21 | M - Exercise | 20,553 D | $0.00 | 2034-02-14 | 20,553 Common Stock | Direct |
| Stock Option (Right to Buy)F5F3 | $0.72 | 2026-08-21 | M - Exercise | 21,055 D | $0.00 | 2031-09-20 | 21,055 Common Stock | Indirect See footnote |
Footnotes (8)
- F1
- This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F2
- This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F3
- Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Show more
- F4
- 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Show more
- F5
- The stock option is fully vested and exercisable. Show more
- F6
- 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Show more
- F7
- This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F8
- This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
Remarks
Title: Chief Operating and Development Officer
Show moreRelated filings at Neumora Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
113
institutional managers reporting a position
Largest by reported value
- Siren, L.L.C. $14.4M
- Black Rock, Inc. $13.2M
- Softbank Group Corp. $10.4M
5%+ Holders · 13D/G
2 filers
-
Paul L Berns 5.1%
Other insiders at Neumora Therapeutics Inc
GET /v1/forms/4/0001610717-26-000385
API docs
View Original SEC Filing